Drug-induced Q-T prolongation

Medical Clinics of North America

Volumn 89, Issue 6, 2005, Pages 1125-1144

  Kao, Louise W ^a,b,d   Furbee, R Brent ^a,b,c  

^a INDIANA UNIVERSITY   (United States)

^b Indiana Poison Center   (United States)

^c INDIANA UNIVERSITY HEALTH   (United States)

^d INDIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BEPRIDIL; CHLORPROMAZINE; DESIPRAMINE; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DROPERIDOL; ENCAINIDE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IBUTILIDE; IMIPRAMINE; ISOPRENALINE; LITHIUM; MAGNESIUM; NICORANDIL; PAROXETINE; PIMOZIDE; PROCAINAMIDE; QUINIDINE; SOTALOL; TERFENADINE; UNINDEXED DRUG; VERAPAMIL;

CARDIOVASCULAR RISK; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; ELECTRIC CONDUCTIVITY; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FOOD AND DRUG ADMINISTRATION; GENETIC PREDISPOSITION; GENETICS; HEART ARRHYTHMIA; HEART CONTRACTION; HUMAN; PATHOPHYSIOLOGY; POTASSIUM TRANSPORT; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; CALCIUM CHANNEL BLOCKERS; DEATH, SUDDEN, CARDIAC; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; POISONING; PSYCHOTROPIC DRUGS; TORSADES DE POINTES;

EID: 26844476445     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2005.06.003     Document Type: Review

References (109)

1. A. Selzer, and H.W. Wray Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias Circulation 30 1964 17 26
2. F. Dessertenne La tachycardie ventriculaire a deux foyers opposés variables Arch Mal Coeur 59 1966 263 272
3. F. Dessertenne, A. Fabiato, and P. Coumel Un chapitre nouveau d'éléctrocardographie: les variations progressives de l'amplitude de l'éléctrocardiogramme Actual Cardiol Angeiol Int (Paris) 15 1966 241 258
4. Arizona Center for Education and Research on Therapeutics. Drug lists by risk groups. Available at: http://www.torsades.org. Accessed February 16, 2005.
5. F. De Ponti, E. Poluzzi, and N. Montanaro Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus Eur J Clin Pharmacol 57 3 2001 185 209
6. B. Darpo Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes Eur Heart J Suppl 3 Suppl K 2001 K70 K80
7. S.H. Thomas Drugs, QT interval abnormalities and ventricular arrhythmias Adverse Drug React Toxicol Rev 13 2 1994 77 102
8. F. De Ponti, E. Poluzzi, and A. Cavalli Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview Drug Saf 25 4 2002 263 286
9. D.M. Roden, J.R. Balser, and A.L. George Jr. Cardiac ion channels Annu Rev Physiol 64 2002 431 475
10. M. Nabauer, D.J. Beuckelmann, and P. Uberfuhr Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle Circulation 93 1 1996 168 177
11. M. Tristani-Firouzi, J. Chen, and J.S. Mitcheson Molecular biology of K(+) channels and their role in cardiac arrhythmias Am J Med 110 1 2001 50 59
12. C. Antzelevitch, and W. Shimizu Cellular mechanisms underlying the long QT syndrome Curr Opin Cardiol 17 1 2002 43 51
13. M.E. Anderson, S.M. Al-Khatib, and D.M. Roden Duke Clinical Research Institute/ American Heart Journal expert meeting on repolarization C. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management Am Heart J 144 5 2002 769 781
14. W. Haverkamp, G. Breithardt, and A.J. Camm The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications: report on a policy conference of the European Society of Cardiology Cardiovasc Res 47 2 2000 219 233
15. S.G. Priori, J. Barhanin, and R.N. Hauer Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III Circulation 99 5 1999 674 681
16. Y.G. Yap, and A.J. Camm Drug induced QT prolongation and torsades de pointes Heart 89 11 2003 1363 1372
17. D.M. Roden, R. Lazzara, and M. Rosen Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS Circulation 94 8 1996 1996 2012
18. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non cardiovascular medicinal products. Available at: http://www.emea.eu.int/pdfs/human/swp/098696en.pdf. Accessed February 16, 2005.
19. S.M. Al-Khatib, N.M. LaPointe, and J.M. Kramer What clinicians should know about the QT interval JAMA 289 16 2003 2120 2127
20. R.C. Owens Jr. QT prolongation with antimicrobial agents: understanding the significance Drugs 64 10 2004 1091 1124
21. Y. Hong, P.M. Rautaharju, and P.N. Hopkins Familial aggregation of QT-interval variability in a general population: results from the NHLBI Family Heart Study Clin Genet 59 3 2001 171 177
22. W.J. Kostis, and J.C. Belina Differences in beat-to-beat variability of the QT interval between day and night Angiology 51 11 2000 905 911
23. T. Emori, and T. Ohe Evaluation of direct respiratory modulation of the QT interval variability Pacing Clin Electrophysiol 22 6 Pt 1 1999 842 848
24. J.J. Ong, J.S. Sarma, and K. Venkataraman Circadian rhythmicity of heart rate and QTc interval in diabetic autonomic neuropathy: implications for the mechanism of sudden death Am Heart J 125 3 1993 744 752
25. R.R. Shah Drug induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity Fundam Clin Pharmacol 16 2002 147 156
26. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 10 2004 1013 1022
27. M.A. Crouch, L. Limon, and A.T. Cassano Clinical relevance and management of drug-related QT interval prolongation Pharmacotherapy 23 7 2003 881 908
28. P.M. Haddad, and I.M. Anderson Antipsychotic-related QTc prolongation, torsade de pointes and sudden death Drugs 62 11 2002 1649 1671
29. I. Splawski, J. Shen, and K.W. Timothy Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 Circulation 102 10 2000 1178 1185
30. N. El-Sherif, and G. Turitto Torsade de pointes Curr Opin Cardiol 18 1 2003 6 13
31. N. El-Sherif, and G. Turitto Torsade de Pointes D.P. Zipes J. Jalite Cardiac electrophysiology, from cell to bedside 4th edition 2004 WB Saunders Philadelphia 689 699
32. M.C. Sanguinetti Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia Ann N Y Acad Sci 868 1999 406 413
33. D.P. Zipes, and H.J. Wellens Sudden cardiac death Circulation 98 21 1998 2334 2351
34. J.S. Mitcheson, J. Chen, and M. Lin A structural basis for drug-induced long QT syndrome Proc Natl Acad Sci USA 97 22 2000 12329 12333
35. T. Yang, D. Snyders, and D.M. Roden Drug block of I(kr): model systems and relevance to human arrhythmias J Cardiovasc Pharmacol 38 5 2001 737 744
36. H.J. Witchel, J.C. Hancox, and D.J. Nutt Psychotropic drugs, cardiac arrhythmia, and sudden death J Clin Psychopharmacol 23 1 2003 58 77
37. E.H. Locati, P. Maison-Blanche, and P. Dejode Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings J Am Coll Cardiol 25 7 1995 1564 1575
38. A.D. Krahn, P. Nguyen-Ho, and G.J. Klein QT dispersion: an electrocardiographic derivative of QT prolongation Am Heart J 141 1 2001 111 116
39. J. Sheehan, I.J. Perry, and M. Reilly QT dispersion, QT maximum and risk of cardiac death in the Caerphilly Heart Study Eur J Cardiovasc Prev Rehabil 11 1 2004 63 68
40. E.F. Wever, and E.O. Robles de Medina Sudden death in patients without structural heart disease J Am Coll Cardiol 43 7 2004 1137 1144
41. Anonymous State-specific mortality from sudden cardiac death - United States, 1999 MMWR Morbid Mortal Wkly Rep 51 6 2002 123 126
42. Z.J. Zheng, J.B. Croft, and W.H. Giles Sudden cardiac death in the United States, 1989 to 1998 Circulation 104 18 2001 2158 2163
43. S.S. Chugh, J. Jui, and K. Gunson Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large US community J Am Coll Cardiol 44 6 2004 1268 1275
44. H.V. Huikuri, A. Castellanos, and R.J. Myerburg Sudden death due to cardiac arrhythmias N Engl J Med 345 20 2001 1473 1482 [see comment]
45. C.M. Albert, C.U. Chae, and F. Grodstein Prospective study of sudden cardiac death among women in the United States Circulation 107 16 2003 2096 2101
46. S.M. Straus, G.S. Bleumink, and J.P. Dieleman The incidence of sudden cardiac death in the general population J Clin Epidemiol 57 1 2004 98 102
47. S. Brown, H. Inskip, and B. Barraclough Causes of the excess mortality of schizophrenia Br J Psychiatry 177 2000 212 217
48. S. Brown Excess mortality of schizophrenia. A meta-analysis Br J Psychiatry 171 1997 502 508
49. J.M. Dekker, E.G. Schouten, and P. Klootwijk Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study Circulation 90 2 1994 779 785
50. J. Robbins, J.C. Nelson, and P.M. Rautaharju The association between the length of the QT interval and mortality in the Cardiovascular Health Study Am J Med 115 9 2003 689 694
51. J.M. Dekker, R.S. Crow, and P.J. Hannan Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study J Am Coll Cardiol 43 4 2004 565 571
52. E.G. Schouten, J.M. Dekker, and P. Meppelink QT interval prolongation predicts cardiovascular mortality in an apparently healthy population Circulation 84 4 1991 1516 1523
53. W.A. Ray, S. Meredith, and P.B. Thapa Antipsychotics and the risk of sudden cardiac death Arch Gen Psychiatry 58 12 2001 1161 1167
54. O.P. Mehtonen, K. Aranko, and L. Malkonen A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland Acta Psychiatr Scand 84 1 1991 58 64
55. N.A. Buckley, I.M. Whyte, and A.H. Dawson Cardiotoxicity more common in thioridazine overdose than with other neuroleptics J Toxicol Clin Toxicol 33 3 1995 199 204
56. A.H. Glassman, and J.T. Bigger Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death Am J Psychiatry 158 11 2001 1774 1782
57. J.G. Reilly, S.A. Ayis, and I.N. Ferrier Thioridazine and sudden unexplained death in psychiatric in-patients Br J Psychiatry 180 2002 515 522
58. M.A. Friedman, J. Woodcock, and M.M. Lumpkin The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281 18 1999 1728 1734
59. R.L. Woosley, Y. Chen, and J.P. Freiman Mechanism of the cardiotoxic actions of terfenadine JAMA 269 12 1993 1532 1536
60. C.M. Pratt, S. Ruberg, and J. Morganroth Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability Am Heart J 131 3 1996 472 480
61. B.P. Monahan, C.L. Ferguson, and E.S. Killeavy Torsades de pointes occurring in association with terfenadine use JAMA 264 21 1990 2788 2790
62. US Food and Drug Administration. Dear Health Care Professional letter regarding terfenadine. Available at: http://www.fda.gov/medwatch/safety/seldane. htm. Accessed February 16, 2005.
63. L.M. DuBuske Second-generation antihistamines: the risk of ventricular arrhythmias Clin Ther 21 2 1999 281 295
64. W. Smalley, D. Shatin, and D.K. Wysowski Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action JAMA 284 23 2000 3036 3039
65. C.H. Yun, R.A. Okerholm, and F.P. Guengerich Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation Drug Metab Dispos 21 3 1993 403 409
66. D.A. Flockhart Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol 16 2 1996 101 103
67. P.K. Honig, D.C. Wortham, and K. Zamani Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences JAMA 269 12 1993 1513 1518
68. R.M. Gowda, I.A. Khan, and G. Punukollu Female preponderance in ibutilide-induced torsade de pointes Int J Cardiol 95 2-3 2004 219 222
69. R.M. Gowda, G. Punukollu, and I.A. Khan Ibutilide-induced long QT syndrome and torsade de pointes Am J Ther 9 6 2002 527 529
70. A.V. Guanzon, and M.A. Crouch Phase IV trial evaluating the effectiveness and safety of dofetilide Ann Pharmacother 38 7-8 2004 1142 1147
71. S. Freeland, C. Worthy, and M. Zolnierz Initiation and monitoring of class III antiarrhythmic agents J Cardiovasc Electrophysiol 14 Suppl 12 2003 S291 S295
72. B.A. Liu, and D.N. Juurlink Drugs and the QT interval - caveat doctor N Engl J Med 351 11 2004 1053 1056
73. Indiana University School of Medicine. Drug interactions. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed February 16, 2005.
74. G.C. Kane, and J.J. Lipsky Drug-grapefruit juice interactions Mayo Clin Proc 75 9 2000 933 942
75. R.E. Benton, P.K. Honig, and K. Zamani Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram Clin Pharmacol Ther 59 4 1996 383 388
76. L. Carlsson, C. Abrahamsson, and B. Andersson Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations Cardiovasc Res 27 12 1993 2186 2193
77. S.G. Priori, C. Napolitano, and P.J. Schwartz Low penetrance in the long-QT syndrome: clinical impact Circulation 99 4 1999 529 533
78. F. Sesti, G.W. Abbott, and J. Wei A common polymorphism associated with antibiotic-induced cardiac arrhythmia Proc Natl Acad Sci USA 97 19 2000 10613 10618
79. P. Yang, H. Kanki, and B. Drolet Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes Circulation 105 16 2002 1943 1948
80. C.R. Bezzina, A.O. Verkerk, and A. Busjahn A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization Cardiovasc Res 59 1 2003 27 36
81. S.G. Priori, J. Barhanin, and R.N. Hauer Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II Circulation 99 4 1999 518 528
82. R.W. Peters, and M.R. Gold The influence of gender on arrhythmias Cardiol Rev 12 2 2004 97 105
83. R.R. Makkar, B.S. Fromm, and R.T. Steinman Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs JAMA 270 21 1993 2590 2597
84. S.N. Ebert, X.K. Liu, and R.L. Woosley Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence J Womens Health 7 1998 547 557
85. R.E. Benton, M. Sale, and D.A. Flockhart Greater quinidine-induced QTc interval prolongation in women Clin Pharmacol Ther 67 4 2000 413 418
86. D.O. Kozhevnikov, K. Yamamoto, and D. Robotis Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns Circulation 105 9 2002 1128 1134
87. T. Yang, and D.M. Roden Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence Circulation 93 3 1996 407 411
88. A.M. Choy, D. Darbar, and S. Dell'Orto Exaggerated QT prolongation after cardioversion of atrial fibrillation J Am Coll Cardiol 34 2 1999 396 401
89. D. Zeltser, D. Justo, and A. Halkin Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors Medicine (Baltimore) 82 4 2003 282 290
90. S. Viskin Long QT syndromes and torsade de pointes Lancet 354 9190 1999 1625 1633
91. R. Prielipp, J. Butterworth, and P. Roberts Magnesium antagonizes the actions of lysophophaticyl choline (LPC) in myocardial cells: a possible mechanism for its antiarrhythmic effects Anesth Analg 80 1995 1083 1087
92. R.M. Gowda, I.A. Khan, and S.L. Wilbur Torsade de pointes: the clinical considerations Int J Cardiol 96 1 2004 1 6
93. A.M. Choy, C.C. Lang, and D.M. Chomsky Normalization of acquired QT prolongation in humans by intravenous potassium Circulation 96 7 1997 2149 2154
94. Y. Morrison, and D.F. Thompson Isoproterenol treatment of torsades de pointes Ann Pharmacother 27 2 1993 189 190
95. W. Shimizu, and C. Antzelevitch Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome Circulation 102 6 2000 706 712
96. Center for Drug Evaluation and Research. Clinical therapeutics and the recognition of drug induced disease. US Food and Drug Administration. Available at: http://www.fda.gov/medwatch/articles/dig/ceart.pdf. Accessed February 16, 2005.
97. Goldman SA, Kennedy DL, Lieberman R. Clinical therapeutics and the recognition of drug-induced disease. US Food and Drug Administration. Available at: http://www.fda.gov/medwatch/articles/dig/rcontent.htm. Accessed February 16, 2005.
98. Goldman SA. The clinical impact of adverse event reporting. US Food and Drug Administration. Available at: http://www.fda.gov/medwatch/articles/medcont/ medcont.htm. Accessed August 3, 2005.
99. R.R. Fenichel, M. Malik, and C. Antzelevitch Drug-induced torsades de pointes and implications for drug development J Cardiovasc Electrophysiol 15 4 2004 475 495
100. K.E. Lasser, P.D. Allen, and S.J. Woolhandler Timing of new black box warnings and withdrawals for prescription medications JAMA 287 17 2002 2215 2220
101. I. Savelieva, G. Yi, and X. Guo Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion Am J Cardiol 81 4 1998 471 477
102. P. Davey How to correct the QT interval for the effects of heart rate in clinical studies J Pharmacol Toxicol Methods 48 1 2002 3 9
103. A.J.J. Wood Thrombotic thrombocytopenic purpura and clopidogrel - a need for new approaches to drug safety N Engl J Med 342 2000 1824 1826
104. A.J. Wood, C.M. Stein, and R. Woosley Making medicines safer - the need for an independent drug safety board N Engl J Med 339 25 1998 1851 1854
105. A.J. Wood The safety of new medicines: the importance of asking the right questions [comment] JAMA 281 18 1999 1753 1754
106. US Food and Drug Administration. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potention of non-antiarrhythmic drugs. Available at: http://www.fda.gov/cder/guidance/6378dft.htm. Accessed February 16, 2005.
107. European Agency for the Evaluation of Medicinal Products. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potention of non-antiarrhythmic drugs. Available at: http://www.emea.eu.int/pdfs/human/ich/ 000204en.pdf. Accessed February 16, 2005.
108. US Food and Drug Administration. ICH S7B: the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Available at: http://www.fda.gov/cber/gdlns/ichqt.pdf. Accessed February 16, 2005.
109. M.A. Howland Pharmacokinetic and toxicokinetic principles L.S. Nelson Goldfrank's toxicologic emergencies 7th edition 2002 McGraw-Hill New York 166 186